Pharmalittle, STAT+: Drugmaker Payment Allegations and Dupixent Competition
Monday, 2 November 2026, 06:22
Pharmalittle, STAT+: Drug Supply and Competition News
A Pharmalittle, STAT+ roundup reports allegations that four major drugmakers paid tens of millions of dollars to middlemen involved in supplying lifesaving medicines to Russian government entities. The supplied description does not name the companies or explain the transactions, so the allegations should be treated as reported claims rather than established findings.
Key developments
- Payments to intermediaries: The report concerns alleged payments tied to medicine supplies for Russian government entities.
- Potential Dupixent competition: The roundup also mentions a possible rival to Dupixent but provides no further details.
For company names, product information, and the reporting behind these items, visit the original STAT+ source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.